Work

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5670

Authors: Toby Eyre, Matthew S Davids, Jeff Sharman, Paul Barr, Catherine Coombs, Wojciech Jurczak, Koji Izutsu, Meghan Thompson, William Wierda, Ying (denise) Wang, Marisa Hill, Donald Tsai, Ching Ching Leow, Sarang Abhyankar, Paolo Ghia, Jennifer Woyach

Institutions: Churchill Hospital, Harvard University, Dana-Farber Cancer Institute, Willamette Valley Cancer Institute and Research Center, University of Rochester Medicine, University of California, Irvine, The Maria Sklodowska-Curie National Research Institute of Oncology, National Cancer Centre Japan, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Eli Lilly (United States), Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417018605

Cites:

Cited by:

Related to: